Home > Insider Trading > Filing (0000899243-21-031635)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1739410	Rallybio Corp	RLYB	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1551966	Lorne Robert Hopfner	C/O Rallybio Corporation 234 Church Street, Suite 1020 New Haven CT 06510		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-07-28	1,694,388	$0.00	1,694,388	No	4	J	Indirect	Pivotal bioVenture Partners Fund I L.P
Common Stock	Acquisiton	2021-08-02	576,923	$13.00	2,267,411	No	4	P	Indirect	Pivotal bioVenture Partners Fund I L.P

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Indirect	Pivotal bioVenture Partners Fund I L.P
No	4	P	Indirect	Pivotal bioVenture Partners Fund I L.P

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Units	Disposition	2021-07-28	10,789,193	$0.00	1,693,488	$0.00
Common Stock	Option (Right to Buy)	Acquisiton	2021-07-28	13,440	$0.00	13,440	$13.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	J	Indirect
13,440			No	4	A	Direct

Footnotes

The Series B Preferred Units (the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation.
Shares of common stock are held directly by Pivotal bioVenture Partners Fund I L.P. ("Pivotal"). Pivotal bioVenture Partners Fund I G.P., L.P. is the general partner of Pivotal. Dr. Hopfner is a managing director at Pivotal bioVenture Partners and may be deemed to share voting and dispositive power over the shares held by Pivotal. Dr. Hopfner disclaims beneficial ownership of the shares held by Pivotal except to the extent of his pecuniary interest therein.
Prior to the effectiveness of the Plan of Liquidation, the Preferred Units were convertible into shares of common units of Rallybio Holdings, LLC.
The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031.